INCYTE CORP shareholders Q3 2023

INCYTE CORP's ticker is INCY and the CUSIP is 45337C102. A total of 516 filers reported holding INCYTE CORP in Q3 2023. The put-call ratio across all filers is 0.75 and the average weighting 0.2%.

INCYTE CORP shareholders Q3 2023
NameSharesValueWeighting ↓
WORLDQUANT MILLENNIUM ADVISORS LLC 726,063$41,944,6600.65%
DODGE & COX 16,416,111$948,358,7320.64%
Teza Capital Management LLC 117,691$6,799,0090.64%
ICON ADVISERS INC/CO 42,900$2,478,3330.61%
SHERBROOKE PARK ADVISERS LLC 32,223$1,861,5230.59%
FORT, L.P. 3,552$205,1990.57%
BRAIDWELL LP 294,900$17,036,3730.54%
JUPITER ASSET MANAGEMENT LTD 812,919$46,962,3310.52%
Pearl River Capital, LLC 56,980$3,291,7350.52%
Andra AP-fonden 139,500$8,058,9150.48%
Renaissance Technologies 4,796,533$277,0960.47%
TOEWS CORP /ADV 13,400$774,1180.47%
OSTRUM ASSET MANAGEMENT 87,470$5,053,1420.47%
AXQ CAPITAL, LP 22,400$1,294,0480.46%
JGP Global Gestao de Recursos Ltda. 12,457$719,6410.46%
Neo Ivy Capital Management 17,908$1,0350.46%
Man Group plc 2,531,618$146,251,5720.45%
HUSSMAN STRATEGIC ADVISORS, INC. 39,000$2,253,0300.43%
GraniteShares Advisors LLC 7,914$457,1920.43%
GRIMES & COMPANY, INC. 189,478$10,946,1440.42%
About INCYTE CORP

Incyte Corp is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel medicines to meet the unmet medical needs of patients. The company has a diverse portfolio of products that are designed to treat a range of diseases, including cancer, autoimmune disorders, and inflammatory conditions.

One of the company's most promising products is Jakafi, a drug that is used to treat patients with myelofibrosis, a rare type of blood cancer. Jakafi has been approved by the FDA and is currently being used by patients around the world. The drug has also shown promise in treating other types of cancers, including pancreatic cancer and acute graft-versus-host disease.

Incyte Corp has a strong pipeline of products that are in various stages of development. The company is currently conducting clinical trials for several products, including ruxolitinib cream, a topical treatment for atopic dermatitis, and pemigatinib, a drug that is being developed to treat cholangiocarcinoma, a type of liver cancer.

The company has a strong management team that is focused on delivering value to shareholders. The CEO, Hervé Hoppenot, has a proven track record of success in the biopharmaceutical industry and has been instrumental in driving the company's growth.

Overall, Incyte Corp is a company that is well-positioned for long-term success. With a strong portfolio of products, a robust pipeline, and a talented management team, the company is poised to continue delivering value to patients and shareholders alike.

It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.

External links

This page lists INCYTE CORP's shareholders in Q3 2023. To view INCYTE CORP's shareholder history, click here.